Active Ingredient History

  • Now
Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl extended-release tablets) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.   NCATS

  • SMILES: COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3
  • Mol. Mass: 389.46
  • ALogP: 1.35
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.1370 - $19.7233
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

afuzosin | alfetim | alfusozine | alfutral sr | alfuzocine | alfuzosin | alfuzosina | alfuzosine | alfuzosin hcl | alfuzosin hydrochloride | alfuzosinum | alphuzosine | benestan | benestan ret | besavar xl | fuzatal xl | kelanu xl | (±)-n-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide | n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide | n-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide | sl 77 | sl-7749910 | sl-77499-10 | urion | urion s | urotraxal | uroxatral | vasran xl | xatral | xatral sr | zufal xl


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue